Академический Документы
Профессиональный Документы
Культура Документы
INTRODUCTION
Founder: Pascal Soriot.
Headquarters: Cambridge.
Subsidiaries: MedImmune
• The Company focuses on three main therapy areas: Oncology,
Cardiovascular & Metabolic Disease and Respiratory, while
selectively pursuing therapies in Autoimmunity, Infection and
Neuroscience.
• They have ten products with global sales above 1 billion dollar.
• The company saw a YoY (Year Over Year) fall of around 5.0% in R&D
expenses. It reduced its SG & A (selling, general, and administrative)
expenses YoY by 9.0% in 2016.
What Next?
Future Growth Drivers:
Farxiga is expected to be a
major revenue driver in
2017.
• Tagrisso, a third-line eGFR-(estimated glomerular filtration rate)
mutated lung cancer drug, reported revenues of $423.0 million in
2016.
• AstraZeneca expects to see a further
rise in Tagrisso’s revenues after it is
launched in China.
How it is done?
• Developing health systems
• Delivering sustainable benefits
• Improving affordability
Programmes:
• Healthy Heart Africa (HHA) is company’s innovative programme
committed to tackling hypertension (high BP) and the increasing burden
of cardiovascular disease (CVD) in Africa.
• HHA aims to reach 10 million hypertensive patients across Africa by
2025.
• Supporting local health systems by increasing awareness of the
symptoms and risks of hypertension and by offering education,
screening, reduced-cost treatment and control.
The Young Health Programme addresses prevention of non-communicable
diseases by reducing the uptake of unhealthy behaviors in young people.
• YHP India has directly been able to reach out to 89,493 young people
(40,271 boys and 49,222 girls) and has influenced 84,387 wider
community members, including health professionals, educators and
policy makers.
• The second vital approach is the training and support of 1,581 Peer
Educators, of which 814 are girls, who are actively responsible for
delivering health messages to other youngsters in school and
communities.
TECHNOLOGY
Driving sustainable growth through innovation!
AstraZeneca is committed to
driving scientific advances in small
molecules, oligonucleotides and
other emerging technology
platforms to push the boundaries of
medical science.
ATM is a key trigger protein in the DNA damage response and a prime
therapeutic target in cancer.
The impact?
Three successful projects:
https://www.astrazeneca.com/
Prepared By –
Mrunali Rane
Mansi Pethani
Faiz Sayyed
Rohil Shelar
Anjali Singh